Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study

Arnon P. Kater,Jenny Wu,Thomas J. Kipps,Barbara Eichhorst,Peter Hillmen,James DRozario,Sarit Assouline,Carolyn Owen,Tadeusz Robak,Javier de la Serna,Ulrich Jaeger,Guillaume Cartron,Marco Montillo,Julie Dubois,Eric Eldering,Clemens Mellink,Anne-Marie van der Kevie-Kersemaekers,Su Young Kim,Brenda Chyla,Elizabeth Punnoose,Christopher R. Bolen,Zoe June Assaf,Yanwen Jiang,Jue Wang,Marcus Lefébure,Michelle Boyer,Kathryn Humphrey,John F. Seymour

Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study

2020

PURPOSEIn previous analyses of the MURANO study, fixed-duration venetoclax plus rituximab (VenR) resulted in improved progression-free survival (PFS) compared with bendamustine plus rituximab (BR) ...

Keywords:

gene mutation
Rituximab
Venetoclax
Bendamustine
Oncology
Relapsed chronic lymphocytic leukemia
Medicine
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations